Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Capital Leases (2024 - 2025)

Evommune (EVMN) has disclosed Capital Leases for 2 consecutive years, with $181000.0 as the latest value for Q4 2025.

  • Quarterly Capital Leases fell 66.17% to $181000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $181000.0 through Dec 2025, down 66.17% year-over-year, with the annual reading at $181000.0 for FY2025, 66.17% down from the prior year.
  • Capital Leases for Q4 2025 was $181000.0 at Evommune, down from $535000.0 in the prior quarter.
  • The five-year high for Capital Leases was $535000.0 in Q4 2024, with the low at $181000.0 in Q4 2025.